Janssen Returns Astellas’s JAK Inhibitor
This article was originally published in PharmAsia News
Executive Summary
A ‘strategic portfolio decision’ is behind the return by Johnson & Johnson company Janssen Biotech of broad rights to Astellas’ oral Janus Kinase (JAK) inhibitor, ASP015K, effective 15 Jan.